ProQR director granted 14,595 share options

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of share options covering 14,595 Ordinary Shares.

Accepted by SEC EDGAR 06/30/2026 - 04:02 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Hinsch Gylvin Lykke received a grant of share options covering 14,595 Ordinary Shares. The options have an exercise price of $1.42 per share, based on the closing market price of the company’s ordinary shares on June 1, 2026.

The options were granted on June 2, 2026, with 25% of the underlying shares vesting and becoming exercisable on June 2, 2027. The remaining 75% vest in 12 substantially equal quarterly installments thereafter, contingent on Lykke’s continued service with ProQR.

Insider Trade Summary

Grant/Award: 14,595 shares

Grant/Award 1 txn

Insider Hinsch Gylvin Lykke

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	14,595	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 14,595 contracts (Direct)

Footnotes (2)

1. F1. The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.
2. F2. 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Key Figures

Options granted: 14,595 options Exercise price: $1.42 per share Underlying shares: 14,595 Ordinary Shares +4 more

7 metrics

Options granted 14,595 options Grant on June 2, 2026 to director Hinsch Gylvin Lykke

Exercise price $1.42 per share Based on June 1, 2026 closing market price

Underlying shares 14,595 Ordinary Shares Shares subject to the granted option

Initial vesting 25% on June 2, 2027 First tranche of option vesting

Remaining vesting 75% in 12 quarterly installments Vesting after June 2, 2027, subject to service

Expiration date June 1, 2036 Option term end for the grant

Post-grant derivative holdings 14,595 options Total derivative securities following transaction

Key Terms

Share Option (Right to Buy), closing market price, Board Compensation Policy, vest and become exercisable, +1 more

5 terms

Share Option (Right to Buy) financial

"security_title: Share Option (Right to Buy)"

closing market price financial

"based upon the closing market price of the Issuer's ordinary shares"

Board Compensation Policy financial

"as determined pursuant to the Issuer's Board Compensation Policy"

vest and become exercisable financial

"25% of the shares subject to such option vest and become exercisable on June 2, 2027"

substantially equal quarterly installments financial

"the remaining 75% vest in 12 substantially equal quarterly installments thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ProQR Therapeutics (PRQR) report for Hinsch Gylvin Lykke?

ProQR reported a compensation-related grant of share options to director Hinsch Gylvin Lykke for 14,595 Ordinary Shares. This award is not an open-market purchase or sale but part of the company’s equity compensation, aligning the director’s incentives with shareholder performance over time.

How many ProQR (PRQR) share options were granted to director Hinsch Gylvin Lykke?

Lykke received share options over 14,595 Ordinary Shares of ProQR Therapeutics. These options give the right to buy that number of shares at a fixed exercise price, subject to the vesting schedule and continued service conditions described in the compensation arrangement.

What is the exercise price of the share options granted to ProQR (PRQR) director Hinsch Gylvin Lykke?

The options have an exercise price of $1.42 per share. This price equals the closing market price of ProQR’s ordinary shares on June 1, 2026, determined under the company’s Board Compensation Policy as disclosed in the Form 4/A filing.

When do Hinsch Gylvin Lykke’s ProQR (PRQR) options start vesting?

Twenty-five percent of the options vest and become exercisable on June 2, 2027. The remaining 75% then vest in 12 substantially equal quarterly installments, provided Lykke continues serving ProQR, creating a multi-year incentive tied to ongoing board service.

What is the vesting structure of the new ProQR (PRQR) share option grant?

The grant vests over several years. First, 25% of the 14,595-share option award vests on June 2, 2027, then the remaining 75% vests in 12 substantially equal quarterly installments, all conditioned on continuous service to ProQR Therapeutics as specified in the filing.

When do the share options granted to ProQR (PRQR) director Hinsch Gylvin Lykke expire?

The options are scheduled to expire on June 1, 2036. After that date, any unexercised portion of the 14,595-share option award will lapse, so potential value from the grant depends on ProQR’s share price performance before that expiration date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hinsch Gylvin Lykke

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
06/03/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$1.42(1)	06/02/2026		A		14,595		(2)	06/01/2036	Ordinary Shares	14,595	$0	14,595	D

Explanation of Responses:

1. The price reported in Column 2 is based upon the closing market price of the Issuer's ordinary shares on June 1, 2026, as determined pursuant to the Issuer's Board Compensation Policy.

2. 25% of the shares subject to such option vest and become exercisable on June 2, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

This Form 4/A amends the Form 4 filed on June 3, 2026 solely to correct the number of share options reported. No other information in the original Form 4 has been changed.

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)